日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse Headache: The Randomized, Placebo-Controlled RESOLUTION Trial

依普汀单抗联合患者教育治疗慢性偏头痛和药物过度使用性头痛:随机、安慰剂对照的 RESOLUTION 试验

Jensen, Rigmor Højland; Lundqvist, Christofer; Schytz, Henrik W; Tassorelli, Cristina; Vernieri, Fabrizio; Lanteri-Minet, Michel; Terwindt, Gisela M; Blumenfeld, Andrew; Tepper, Stewart J; Josiassen, Mette Krog; Jansson, Gary; Ettrup, Anders; Mittoux, Aurélia; Lipton, Richard B

Long-term tolerability and effectiveness of eptinezumab in Japanese adults with chronic migraine: results of the 60-week open-label SUNSET trial

艾普汀单抗治疗日本慢性偏头痛成年患者的长期耐受性和有效性:为期 60 周的开放标签 SUNSET 试验结果

Takeshima, Takao; Danno, Daisuke; Imai, Noboru; Suzuki, Keisuke; Ettrup, Anders; Jensen, Sidsel; Josiassen, Mette Krog; Mittoux, Aurélia; Matsumori, Yasuhiko

Adding eptinezumab to brief patient education to treat chronic migraine and medication-overuse headache: Protocol for RESOLUTION-A phase 4, multinational, randomized, double-blind, placebo-controlled study

在简短的患者教育中加入eptinezumab治疗慢性偏头痛和药物过度使用性头痛:RESOLUTION-A 4期多中心随机双盲安慰剂对照研究方案

Jensen, Rigmor H; Schytz, Henrik Winther; Tassorelli, Cristina; Terwindt, Gisela M; Carlsen, Louise N; Mittoux, Aurélia; Østerberg, Ole; Lipton, Richard B; Tepper, Stewart J; Blumenfeld, Andrew; Lundqvist, Christofer